A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Catalyst Pharmaceuticals (NASDAQ:CPRX) has received diverse analyst ratings over the past three months, with a mix of bullish and somewhat bullish sentiments. Analysts have set a 12-month average price target of $28.43, with a high of $34.00 and a low of $23.00. The company's financial metrics show strong net margins, ROE, and ROA, but its revenue growth lags behind industry peers.
June 03, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals has received a mix of bullish and somewhat bullish ratings from analysts, with a 12-month average price target of $28.43. The company's financial metrics are strong, but its revenue growth lags behind industry peers.
The majority of analysts have a positive outlook on CPRX, with a high average price target. The company's strong financial metrics, such as net margin, ROE, and ROA, support a positive short-term impact. However, the lag in revenue growth compared to peers may temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100